Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Development includes a decentralized companion diagnostic intended to expand patient access to PrGIS in global markets.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (MYGN) and SOPHiA GENETICS (SOPH) announced a collaboration to advance prostate cancer genomic instability score technology with AstraZeneca. Myriad’s PrGIS is a biomarker signature designed to assess chromosome instability associated with homologous recombination deficiency, an impaired DNA repair process. The collaboration aims to advance PrGIS in clinical trials and develop potential companion diagnostics, tests used to guide treatment selection.
Myriad’s MyChoice CDx, currently a companion diagnostic in ovarian cancer, will produce the score and is being advanced for a prostate cancer indication. SOPHiA GENETICS is developing a decentralized companion diagnostic incorporating PrGIS, aiming to expand global access. Myriad plans to present research co-authored with AstraZeneca at ESMO Congress 2026; it expects the research to further characterize PrGIS and support validation.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.PrGIS collaboration with SOPHiA GENETICS and AstraZeneca aims to advance Myriad’s technology in clinical trials.
- Minor point. Forward-looking: it has not happened yet and may not happen.MyChoice CDx is being advanced for a new prostate cancer indication and will produce the PrGIS score.
- Minor point. Forward-looking: it has not happened yet and may not happen.SOPHiA GENETICS’ diagnostic development will incorporate Myriad’s PrGIS, aiming to expand global patient access.
- Minor point. Forward-looking: it has not happened yet and may not happen.ESMO Congress 2026 research is expected by Myriad to further characterize PrGIS and support validation.
Negative
- None.
Details
Market move: MYGN -3.27% vs previous close. PrGIS partnership
On Oct 8, the day this news came out, the latest delayed price for MYGN is 3.27% below the previous close. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $4.14.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Terms
chromosomal instability medical
homologous recombination deficiency medical
companion diagnostic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions.
Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where HRD is emerging as an important prognostic and predictive biomarker. The proprietary MyChoice® CDx test which is currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication.
“This collaboration showcases Myriad’s biopharma capabilities to support development of precision oncology treatments,” said Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics. “PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies.”
As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution. The solution will incorporate Myriad’s PrGIS technology and aim to expand patient access to PrGIS in global markets. SOPHiA GENETICS’ technology-agnostic, cloud-based platform offers local laboratory testing across a global network of more than 1,000 connected institutions in over 75 countries.
“Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world,” said Jess Lambe, VP & Managing Director of BioPharma Business Development, SOPHiA GENETICS. “By pairing Myriad’s world-class biomarker innovation with SOPHiA GENETICS’ global network, we are working toward a solution for this. Together, we’re building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most.”
Upcoming ESMO data to highlight PrGIS as a novel biomarker in prostate cancer
Myriad also plans to present PrGIS research, co-authored with AstraZeneca, at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. The research is expected to further characterize the biomarker and support its validation. Full data will be available following the ESMO embargo period.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDMTM, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the development, evaluation, deployment and potential commercialization of the company’s PrGIS technology and MyChoice Cdx, including for prostate cancer as a new indication, in clinical trials and as companion diagnostic solutions for precision oncology therapies; the development and global deployment of a decentralized companion diagnostic solution incorporating PrGIS; the anticipated benefits of the collaboration among the company, SOPHiA GENETICS and AstraZeneca; and the company’s plans to present PrGIS research at ESMO Congress 2026. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contacts
Matt Scalo
(801) 584-3532
IR@myriad.com
Kellen Sanger
IR@sophiagenetics.com
Media Contacts
Andria Rosell
(385) 202-3510
PR@myriad.com
Sarah Mack
media@sophiagenetics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Myriad Genetics’ PrGIS collaboration with SOPHiA GENETICS and AstraZeneca intended to achieve?
The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostics. SOPHiA GENETICS is developing a decentralized diagnostic solution incorporating Myriad’s prostate cancer biomarker technology.
When will the full data from Myriad Genetics’ ESMO PrGIS research be available?
Full data will be available following the ESMO embargo period. Myriad plans to present the research, co-authored with AstraZeneca, at ESMO Congress 2026.